While drug-metabolizing and transport enzyme panels are important in pharmacogenetics, there is evidence that in highly multifactorial diseases such as hypertension there are other genetic factors that strongly affect a patient’s response to therapies. Dr. Ryan Sprissler of Geneticure will discuss a study examining these genetic determinants of hypertension therapy response that has shown that common and functional genetic variation plays a role in the variability of treatment effectiveness and may modulate the bell-curve response to many therapies.
Ryan Sprissler, Ph.D
Chief Scientific Officer, Geneticure Inc.
Dr. Sprissler serves as the co-founder and Chief Scientific Officer of Geneticure, a pharmacogenetics testing company specializing in evidence-based development of PGx testing. With more than 15 years of experience in genetic assay design and testing, he is a current member of the Association for Biomolecular Resource Facilities, the Association for Laboratory Automation, and the American Association for the Advancement of Science, and serves on the board of the Shay Emma Hammer Research Foundation.